- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Daratumumab Lengthens PFS in Multiple Myeloma, but Increases Risk of Neutropenia
Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia.
Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia, according to a study published in a New England Journal of Medicine.
Researchers assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib and dexamethasone alone or in combination of daratumumab.
“Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia than bortezomib and dexamethasone alone,” the researchers concluded.
Neutropenia was one of the most common grade 3 or 4 adverse events reported in both groups. However, despite being a common adverse event in both group, the rate was much higher in the daratumumab group.
In the group that received daratumumab, 12.8% reported neutropenia compared with just 4.2% of the control group that received just bortezomib and dexamethasone alone.
However, the 12-month rate of progression-free survival was 60.7% in the daratumumab group compared with just 26.9% in the control group.
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
